Investing

Opposition to PBM Merger Already Speaks Out! (ESRX, MHS)

The mega-PBM that is being created by the merger of Medco Health Solutions, Inc. (NYSE: MHS) and Express Scripts Inc. (NASDAQ: ESRX) is already being protested. Since the merger was announced, 24/7 Wall St. has received many watch-group emails protesting this merger as being anti-competitive or anti-consumer. Former Congresswoman Eva M. Clayton, chairwoman of the Preserve Community Pharmacy Access NOW! coalition, noted that this harmful mega-PBM merger must be stopped after the nationwide coalition responded after the FTC voted 3-1 to close this merger investigation.

Then there is another one from Pharmacists United for Truth and Transparency, an independent watchdog organization dedicated to exposing the role PBMs play in driving up prescription drug costs for consumers and employers. This group noted that drug costs will rise and the group denounced the deal as a license to price-gouge the consumer. Specifically, its press release cited the following: “The FTC has given the PBMs the green light to consolidate their outsized power and continue driving up the costs of prescription drugs. The decision will negatively impact plan sponsors that contract with PBMs and consumers looking for affordable medication.”

Investors who made bets on this merger are certainly happy. We are not exactly convinced that this merger’s “savings” will be passed on directly to the consumer as much as the companies have represented. We will see …

JON C. OGG

Get Ready To Retire (Sponsored)

Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Get started right here.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.